SIOX VS AZN Stock Comparison

PerformanceForecastTechnicalsVolatilityDividendProfitAnalyst Price TargetsSentimentEarnings
PerformanceForecastTechnicalsVolatilityDividendProfitAnalyst Price TargetsSentimentEarnings

Performance

SIOX
10/100

SIOX returned -58.25% in the last 12 months. Based on the other stocks in it's sector, it's performance is below average giving it a grade of 10 of 100.

AZN
100/100

AZN returned 6.03% in the last 12 months. Based on SPY's performance of -21.20%, its performance is above average giving it a score of 100 of 100.

Forecast

SIOX
82/100

The 38 analysts offering 12-month price forecasts for SIOX have an average target of 0, with a high estimate of 0 and a low estimate of 0 giving it a grade of 82 of 100.

AZN

"Forecast" not found for AZN

Technicals

SIOX
86/100

Based on a multitude of SIOX's technicals indicators, it receives a grade of 85 of 100.

AZN
11/100

AZN receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Volatility

SIOX
10/100

SIOX had a -3,007.89% lower max drawdown compared to SPY over the last 12 months giving it a grade of 10 of 100.

AZN
48/100

AZN has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Dividend

SIOX
10/100

SIOX does not have a dividend payout ratio.

AZN

"Dividend" not found for AZN

Profit

SIOX
10/100

Could not get data for SIOX.

AZN
77/100

Out of the last 20 quarters, AZN has had 18 profitable quarters and has increased their profits year over year on 9 of them.

Analyst Price Targets

SIOX

"Analyst Price Targets" not found for SIOX

AZN
85/100

5 analysts offer 12-month price targets for AZN. Together, they have an average target of 80.5, the most optimistic target put AZN at 82 within 12-months and the most pessimistic has AZN at 79.

Sentiment

SIOX

"Sentiment" not found for SIOX

AZN
70/100

AZN had a bullish sentiment score of 70.02% across Twitter and StockTwits over the last 12 months. It had an average of 101.58 posts, 140.17 comments, and 324.32 likes per day.

Earnings

SIOX

"Earnings" not found for SIOX

AZN
56/100

AZN has missed earnings 3 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

Sio Gene Therapies Inc. Common Stock Summary

Nasdaq / SIOX
Healthcare
Biotechnology
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

AstraZeneca PLC Summary

Nasdaq / AZN
Healthcare
Drug Manufacturers - General
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.